Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.
- Breast Cancer
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- At least 18 years of age.
- Postmenopausal as confirmed in medical history
- Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB (Institutional Review Board)/Ethics Committee.
- Estrogen receptor positive breast cancer. Body mass index of 30 or greater.
- Consented for tissue collection on CTRC (Cancer Therapy and Research Center) repository 07-32
- Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)
- Chronic use of NSAIDs (nonsteroidal anti-inflammatory drugs) aspirin or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)
- Any NSAIDs aspirin or omega-3 free fatty acid supplementation within the last 14 days
- History of medical noncompliance
- Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days
- Early Phase 1
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Basic Science
- None (Open Label)
|Letrozole 2.5 mg by mouth daily for 30 days.||
|Fish oil 2700 mg by mouth daily for 30 days.||
Letrozole and Fish Oil
|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.||
- The University of Texas Health Science Center at San Antonio
Study ContactEpp Goodwin
Prospective, comparative, three arm, short term, non-interventional study with correlative biomarker endpoints. Sixty (60) obese (≥ 30 BMI) newly diagnosed ER+ postmenopausal breast cancer patients will be recruited to participate in a short term (30 day) Phase 0 biomarker evaluation study prior to surgical resection.